Axsome Therapeutics
AXSM
163 hedge funds and large institutions have $1.34B invested in Axsome Therapeutics in 2020 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 64 increasing their positions, 40 reducing their positions, and 47 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 40
45% more call options, than puts
Call options by funds: $107M | Put options by funds: $73.4M
0.82% more ownership
Funds ownership: 60.79% → 61.61% (+0.82%)
4% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 47
4% less funds holding
Funds holding: 169 → 163 (-6)
33% less funds holding in top 10
Funds holding in top 10: 12 → 8 (-4)
42% less capital invested
Capital invested by funds: $2.31B → $1.34B (-$965M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$125M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$55.8M |
| 3 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$42.2M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$25.3M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$25.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$70.2M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$45.7M |
| 3 |
HM
HealthCor Management
New York
|
-$42.2M |
| 4 |
Millennium Management
New York
|
-$28.7M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$27.1M |
AXSM Hedge Fund Activity: Q1 2020 in Review
163 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q1 2020, worth a combined $1.34B — down 42% from $2.31B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of AXSM and 45 opened new positions — a net loss of 2 holders — while 40 trimmed existing stakes and 64 added.
The largest buyer was RA Capital Management, adding an estimated $125M. The largest seller was T. Rowe Price Associates, cutting an estimated $70.2M.
- 163 institutional investors held Axsome Therapeutics (AXSM) as of Q1 2020, down from 169 in Q4 2019.
- Funds reported $1.34B of Axsome Therapeutics stock for Q1 2020, down 42% quarter-over-quarter.
- 45 funds opened new Axsome Therapeutics positions in Q1 2020 and 47 closed out, a net change of -2 holders.
- The largest Axsome Therapeutics buyer in Q1 2020 was RA Capital Management, an estimated $125M added.
- The largest Axsome Therapeutics seller in Q1 2020 was T. Rowe Price Associates, an estimated $70.2M sold.
Based on aggregated 13F filings for Q1 2020.